Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1400 of 1475 entries
View as:

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04099251 Org: User:
Start: 10/28/19 End: 06/29/27 Due: 06/29/28

Abatacept Post-marketing Clinical Study in Japan

Phase: N/A Priority: Normal
NCT ID: NCT01758198 Org: User:
Start: 04/11/13 End: 12/26/16 Due: 12/26/17

PPAR-COMBO With Sulfonylurea

Phase: N/A Priority: Normal
NCT ID: NCT00162175 Org: User:
Start: 07/31/03 End: 11/30/05 Due: 11/30/06

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06697197 Org: User:
Start: 02/17/25 End: 01/05/29 Due: 01/05/30

A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT03426618 Org: User:
Start: 01/12/18 End: 03/13/19 Due: 03/13/20

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00122382 Org: User:
Start: 07/31/05 End: 02/28/09 Due: 02/28/10

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00048932 Org: User:
Start: 12/31/02 End: 10/31/09 Due: 10/31/10

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

Phase: N/A Priority: Normal
NCT ID: NCT00252005 Org: User:
Start: 11/30/05 End: 02/28/07 Due: 02/28/08

DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation

Phase: N/A Priority: Normal
NCT ID: NCT05838781 Org: User:
Start: 12/04/23 End: 05/16/24 Due: 05/16/25

Phase IIIB Subcutaneous Missed Dose Study

Phase: N/A Priority: Normal
NCT ID: NCT00533897 Org: User:
Start: 11/30/07 End: 02/28/14 Due: 02/28/15

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03068455 Org: User:
Start: 04/11/17 End: 02/02/21 Due: 02/02/22

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT03200977 Org: User:
Start: 07/01/16 End: 06/03/22 Due: 06/03/23

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT06090539 Org: User:
Start: 12/29/23 End: 10/28/28 Due: 10/28/29

Early Post-marketing Study of Eliquis (Apixaban)

Phase: N/A Priority: Normal
NCT ID: NCT02153424 Org: User:
Start: 04/30/14 End: 11/30/15 Due: 11/30/16

A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00534807 Org: User:
Start: 09/30/07 End: 11/30/08 Due: 11/30/09

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00024284 Org: User:
Start: 06/30/01 End: 12/31/03 Due: 12/31/04

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Phase: N/A Priority: Normal
NCT ID: NCT01046864 Org: User:
Start: 02/28/10 End: 06/30/14 Due: 06/30/15

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT03934216 Org: User:
Start: 07/01/19 End: 04/04/23 Due: 04/04/24

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

Phase: N/A Priority: Normal
NCT ID: NCT00002224 Org: User:
Start: 03/31/99 End: 03/31/99 Due: 03/31/00

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04109066 Org: User:
Start: 11/18/19 End: 12/27/23 Due: 12/27/24

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01420770 Org: User:
Start: 08/31/11 End: 04/30/14 Due: 04/30/15

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06452329 Org: User:
Start: 02/28/24 End: 07/31/25 Due: 07/31/26

Long-term Data Collection for Subjects in MDX-010 Studies

Phase: N/A Priority: Normal
NCT ID: NCT00928031 Org: User:
Start: 06/30/07 End: 04/30/09 Due: 04/30/10

A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials

Phase: N/A Priority: Normal
NCT ID: NCT01337479 Org: User:
Start: 02/28/03 End: 09/30/10 Due: 09/30/11

A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex

Phase: N/A Priority: Normal
NCT ID: NCT00002246 Org: User:
Start: 10/31/97 End: 03/31/99 Due: 03/31/00